The Role of Parathyroid Hormone in the Management of Osteoporosis
- 1 November 2005
- journal article
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 64 (Suppl. 2), 81-85
- https://doi.org/10.1159/000087762
Abstract
It has been over 2 years since parathyroid hormone (PTH 1-34) was approved in the US and Europe for the treatment of osteoporosis in postmenopausal women and men. Clinical experience with this peptide has enhanced confidence in its use and its application in specific clinical scenarios. There is no doubt that PTH 1-34 is safe and effective in reducing spine and non-vertebral fractures in men and women. However, the lack of several randomized placebo-controlled trials and their relatively short duration raise several questions that still need to be answered. This paper reviews three major areas of uncertainty: (1) Is there significant heterogeneity in the bone density response of individuals to PTH? If so, what factors are important predictors? (2) What other regimens are available for PTH use? (3) What, if anything, should the clinician do after PTH is discontinued? Answers to these questions will undoubtedly lead to even greater utilization of this drug and some of its future derivatives.Keywords
This publication has 14 references indexed in Scilit:
- The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1?34)]Osteoporosis International, 2004
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisNew England Journal of Medicine, 2003
- Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] on Cortical Bone in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2003
- Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosisOsteoporosis International, 2003
- Parathyroid Hormone Induces Interleukin-6 Gene Expression in Bone Stromal Cells of Young Rats.The Journal of Veterinary Medical Science, 2002
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cellsActa Endocrinologica, 2000
- Prevention of Estrogen Deficiency–Related Bone Loss With Human Parathyroid Hormone–(1-34)JAMA, 1998
- Bone-selective analogs of human PTH(1–34) increase bone formation in an ovariectomized rat modelJournal of Bone and Mineral Research, 1996
- Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol.JCI Insight, 1993